المؤلفون: Fontán-Vela, Mario, Hernando Sebastian, Victoria, Olmedo, Carmen, Coma, Ermengol, Martínez, Montse, Moreno-Perez, David, Lorusso, Nicola, Vázquez Torres, María, Barbas del Buey, José Francisco, Roig-Sena, Javier, Pastor, Eliseo, Galmés Truyols, Antònia, Artigues Serra, Francisca, Sancho Martínez, Rosa María, Latasa Zamalloa, Pello, Pérez Martínez, Olaia, Vázquez Estepa, Ana, García Rojas, Amós José, Barreno Estévez, Ana Isabel, Sánchez-Migallón Naranjo, Alonso, Pérez Martín, Jaime Jesús, Peces Jiménez, Pilar, Morales Romero, Raquel, Castilla, Jesús, García Cenoz, Manuel, Huerta Huerta, Marta, Boone, An Lieve Dirk, Macías Ortiz, María José, Álvarez Río, Virginia, Rodríguez Recio, María Jesús, Merino Díaz, María, Berradre Sáenz, Belén, Villegas-Moreno, María Teresa, Limia, Aurora, Diaz Franco, Asuncion, Monge Corella, Susana, Spanish MPOX vaccine effectiveness study group, Jarrin-Vera, Inmaculada

مصطلحات موضوعية: mpox, Monkeypox, Vaccine effectiveness, MVA-BN vaccine, Pre-exposure prophylaxis

الوصف: Background: With over 7,500 cases notified since April 2022, Spain has experienced the highest incidence of mpox in Europe. From July 12th onwards, the Modified Vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for individuals at high-risk of mpox, including those receiving pre-exposure prophylaxis for HIV (HIV-PrEP). Our aim was to assess the effectiveness of one dose of MVA-BN vaccine as pre-exposure against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods: We conducted a national retrospective cohort study between July 12 and December 12, 2022. Individuals ≥18 years, receiving HIV-PrEP as of July 12 and with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of MVA-BN vaccine and unvaccinated controls of the same age group and region. We used a Kaplan-Meier estimator and calculate risk ratios (RR) and vaccine effectiveness (VE = 1-RR). Results: We included 5,660 matched pairs, with a median follow-up of 62 days (interquartile range 24-97). Mpox cumulative incidence was 5.6 per 1,000 (25 cases) in unvaccinated and 3.5 per 1,000 (18 cases) in vaccinated. No effect was found during days 0-6 post-vaccination (VE -38.3; 95% confidence interval (95%CI): -332.7; 46.4), but VE was 65% in ≥7 days (95%CI 22.9; 88.0) and 79% in ≥14 days (95%CI 33.3; 100.0) post-vaccination. Conclusions: One dose of MVA-BN vaccine offered protection against mpox in a most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time. ; Sí

العلاقة: https://doi.org/10.1093/cid/ciad645Test; Clin Infect Dis. 2024 Feb 17;78(2):476-483.; http://hdl.handle.net/20.500.12105/16837Test; Clinical Infectious Diseases

الإتاحة: https://doi.org/20.500.12105/16837Test
https://doi.org/10.1093/cid/ciad645Test
https://hdl.handle.net/20.500.12105/16837Test

المؤلفون: Fontán-Vela, Mario, Hernando, Victoria, Olmedo, Carmen, Coma, Ermengol, Martínez, Montse, Moreno-Perez, David, Lorusso, Nicola, Vázquez Torres, María, Barbas del Buey, José Francisco, Roig-Sena, Javier, Pastor, Eliseo, Galmés Truyols, Antònia, Artigues Serra, Francisca, Sancho Martínez, Rosa María, Latasa Zamalloa, Pello, Pérez Martínez, Olaia, Vázquez Estepa, Ana, García Rojas, Amós José, Barreno Estévez, Ana Isabel, Sánchez-Migallón Naranjo, Alonso, Pérez Martín, Jaime Jesús, Peces Jiménez, Pilar, Morales Romero, Raquel, Castilla, Jesús, García Cenoz, Manuel, Huerta Huerta, Marta, Boone, An Lieve Dirk, Macías Ortiz, María José, Álvarez Río, Virginia, Rodríguez Recio, María Jesús, Merino Díaz, María, Berradre Sáenz, Belén, Villegas-Moreno, María Teresa, Limia, Aurora, Diaz, Asuncion, Monge, Susana, Rodrigo, José Antonio Lluch, Juaneda, Juan, Malonda, Rosa Carbo, Mendioroz, Jacobo, Farran, Joan Colom, Carril, Fernando González, Echevarría, Lorea Oscoz, Barros, María Teresa Otero, Gaiche, Nuria Suárez, Martínez, José Angélica Gómez, Bastante, Borja Alcázar, Santos, Rocío Sánchez, Sanjurjo, Lucía Fuster, del Carmen Pacheco Martínez, María

المصدر: Clinical Infectious Diseases ; volume 78, issue 2, page 476-483 ; ISSN 1058-4838 1537-6591

الوصف: Background With more than 7500 cases reported since April 2022, Spain has experienced the highest incidence of mpox in Europe. From 12 July onward, the modified vaccinia Ankara-Bavaria Nordic (MVA-BN) smallpox vaccine was offered as pre-exposure prophylaxis for those receiving pre-exposure prophylaxis for human immunodeficiency virus (HIV-PrEP). Our aim was to assess the effectiveness of 1 dose of MVA-BN vaccine as pre-exposure prophylaxis against mpox virus (MPXV) infection in persons on HIV-PrEP. Methods National retrospective cohort study between 12 July and 12 December 2022. Individuals aged ≥18 years receiving HIV-PrEP as of 12 July with no previous MPXV infection or vaccination were eligible. Each day, we matched individuals receiving a first dose of vaccine and unvaccinated controls of the same age and region. We used a Kaplan–Meier estimator, calculated risk ratios (RR) and vaccine effectiveness (VE = [1 − RR]x100). Results We included 5660 matched pairs, with a median follow-up of 62 days (interquartile range, 24–97). Mpox cumulative incidence was 5.6 per 1000 (25 cases) in unvaccinated and 3.5 per 1000 (18 cases) in vaccinated. No effect was found during days 0–6 post-vaccination (VE, −38.3; 95% confidence interval [CI], −332.7 to 46.4), but VE was 65% at ≥7 days (95% CI, 22.9 to 88.0) and 79% at ≥14 days (95% CI, 33.3 to 100.0) post-vaccination. Conclusions One dose of MVA-BN vaccine offered protection against mpox in most-at-risk population shortly after the vaccination. Further studies need to assess the VE of a second dose and the duration of protection over time.

الإتاحة: https://doi.org/10.1093/cid/ciad645Test
https://academic.oup.com/cid/article-pdf/78/2/476/56697890/ciad645.pdfTest

المؤلفون: Palladino, Claudia, Gómez, María Luisa Navarro, Soler-Palacín, Pere, González-Tomé, María Isabel, De Ory, Santiago J., Espiau, María, Hoyos, Santiago Pérez, León-Leal, Juan Antonio, Méndez, María, Moreno-Pérez, David, Guasch, Claudia Fortuny, Sierra, Antoni Mur, Guruceta, Itziar Pocheville, Guillén, Santiago Moreno, Briz, Verónica, CoRISpe Working Group

مصطلحات موضوعية: adolescents, children, HAART, HIV-1, maraviroc

الوصف: Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. ; Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs. ; Financial support was received from Instituto de Salud Carlos III through the Red Temática de Investigación Cooperativa en Sida (ISCIII-RETIC RD06/006) and by grants from Instituto de Salud Carlos III (grant number: MPY 1039/14 to V.B.], FIPSE (grant number: 36-0910-10) and RIS (grant number: RD12/0017/0035 y RD12/0017/0037). C.P. is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (grant number SFRH/BPD/77448/2011). V.B. is supported by the Miguel Servet programme from Fondo de Investigación Sanitaria (ISCIII) (grant number CP13/00098). ; info:eu-repo/semantics/publishedVersion

العلاقة: info:eu-repo/grantAgreement/FCT/OE/SFRH%2FBPD%2F77448%2F2011/PT; https://journals.lww.com/aidsonline/fulltext/2015/10230/off_label_use_of_maraviroc_in_hiv_1_infected.15.aspxTest; Palladino C, Gómez MLN, Soler-Palacín P, González-Tomé MI, De Ory SJ, Espiau M, et al. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS [Internet]. 23 de outubro de 2015;29(16):2155–9. Disponível em: https://journals.lww.com/00002030-201510230-00015Test; http://hdl.handle.net/10451/62088Test; cv-prod-1185529; 2-s2.0-84964904223

الإتاحة: https://doi.org/10.1097/QAD.0000000000000819Test
http://hdl.handle.net/10451/62088Test

المؤلفون: de Felipe, Beatriz, Obando Pacheco, Pablo, Carazo Gallego, Begoña, López Martín, David, Santos Pérez, Juan Luis, González Jiménez, Yolanda, Muñoz Vilches, María José, Cardelo Autero, Nerea, González Galán, Verónica, Morón, Francisco José, Cordero Varela, Juan Antonio, Torres Sánchez, María José, Medina Claros, Antonio, Moreno Pérez, David, Obando, Ignacio

مصطلحات موضوعية: Genotypes, Streptococcus pneumoniae, invasive pneumococcal disease, pneumococcal conjugate vaccine, serotypes, Child, Humans, Molecular Epidemiology, Pneumococcal Infections, Pneumococcal Vaccines, Prospective Studies, Spain, Vaccines, Conjugate

الوصف: This study aimed to assess the impact of the introduction of pneumococcal conjugate vaccine 13 (PCV13) on the molecular epidemiology of invasive pneumococcal disease (IPD) in children from Andalusia. A population-based prospective surveillance study was conducted on IPD in children aged

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10668/22580Test; PMC9727655; https://www.cambridge.org/core/services/aop-cambridge-core/content/view/AFEB3E9440E11D50F47F73E24E0353CC/S0950268822001376a.pdf/div-class-title-molecular-epidemiology-of-paediatric-invasive-pneumococcal-disease-in-andalusia-spain-div.pdfTest; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727655/pdfTest

الإتاحة: https://doi.org/10.1017/S0950268822001376Test
http://hdl.handle.net/10668/22580Test
https://www.cambridge.org/core/services/aop-cambridge-core/content/view/AFEB3E9440E11D50F47F73E24E0353CC/S0950268822001376a.pdf/div-class-title-molecular-epidemiology-of-paediatric-invasive-pneumococcal-disease-in-andalusia-spain-div.pdfTest
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727655/pdfTest

المؤلفون: Felipe, Beatriz de, Obando-Pacheco, Pablo, Carazo-Gallego, Begoña, López Martín, David, Santos Pérez, Juan Luis, González Jiménez, Yolanda, Muñoz Vilches, María José, Cardelo Autero, Nerea, González Galán, Verónica, Morón, Francisco J., Cordero Varela, Juan Antonio, Torres-Sánchez, María José, Medina Claros, Antonio, Moreno-Pérez, David, Obando, Ignacio

المساهمون: Pfizer, López Martín, David, Obando, Ignacio

مصطلحات موضوعية: Genotypes, Streptococcus pneumoniae, Invasive pneumococcal disease, Pneumococcal conjugate vaccine, Serotypes

الوصف: This study aimed to assess the impact of the introduction of pneumococcal conjugate vaccine 13 (PCV13) on the molecular epidemiology of invasive pneumococcal disease (IPD) in children from Andalusia. A population-based prospective surveillance study was conducted on IPD in children aged <14 years from Andalusia (2018-2020). Pneumococcal invasive isolates collected between 2006 and 2009 in the two largest tertiary hospitals in Andalusia were used as pre-PCV13 controls for comparison of serotype/genotype distribution. Overall IPD incidence rate was 3.55 cases per 100 000 in 2018; increased non-significantly to 4.20 cases per 100 000 in 2019 and declined in 2020 to 1.69 cases per 100 000 (incidence rate ratio 2020 vs. 2019: 0.40, 95% confidence interval (CI) 0.20-0.89, P = 0.01). Proportion of IPD cases due to PCV13 serotypes in 2018-2020 was 28% (P = 0.0001 for comparison with 2006-2009). Serotypes 24F (15%) and 11A (8.3%) were the most frequently identified non-PCV13 serotypes (NVT) in 2018-2020. Penicillin- and/or ampicillin-resistant clones mostly belonged to clonal complex 156 (serotype 14-ST156 and ST2944 and serotype 11A-ST6521). The proportion of IPD cases caused by PCV13 serotypes declined significantly after the initiation of the PCV13 vaccination programme in 2016. Certain NVT, such as serotypes 24F and 11A, warrant future monitoring in IPD owing to invasive potential and/or antibiotic resistance rates. ; This work was supported by Pfizer (grant 53233485). ; Peer reviewed

وصف الملف: application/pdf

العلاقة: Publisher's version; https://doi.org/10.1017/S0950268822001376Test; Sí; Epidemiology and Infection 150: e163 (2022); http://hdl.handle.net/10261/306805Test; http://dx.doi.org/10.13039/100004319Test; 2-s2.0-85136993575; https://api.elsevier.com/content/abstract/scopus_id/85136993575Test

الإتاحة: https://doi.org/10.1017/S095026882200137610.13039/100004319Test
http://hdl.handle.net/10261/306805Test
https://api.elsevier.com/content/abstract/scopus_id/85136993575Test

المؤلفون: Martín Pedraz, Laura, Carazo Gallego, Begoña, Moreno Pérez, David

المصدر: Anales de Pediatría (English Edition) ; volume 95, issue 1, page 4-10 ; ISSN 2341-2879

مصطلحات موضوعية: Management of Technology and Innovation

الإتاحة: https://doi.org/10.1016/j.anpede.2020.04.023Test
https://api.elsevier.com/content/article/PII:S2341287921001046?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2341287921001046?httpAccept=text/plainTest

المؤلفون: Martín Pedraz, Laura, Carazo Gallego, Begoña, Moreno Pérez, David

المصدر: Anales de Pediatría ; volume 95, issue 1, page 4-10 ; ISSN 1695-4033

مصطلحات موضوعية: Pediatrics, Perinatology and Child Health

الإتاحة: https://doi.org/10.1016/j.anpedi.2020.04.031Test
https://api.elsevier.com/content/article/PII:S1695403320302356?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1695403320302356?httpAccept=text/plainTest

المؤلفون: Valdivielso Martínez, Ana Isabel, Ramos Fernández, Jose Miguel, Pérez Frías, Javier, Moreno Pérez, David

المساهمون: Valdivielso Martínez,AI Pediatría Distrito Sanitario Málaga-Guadalhorce, Pediatría Hospital Regional Universitario de Málaga, Programa del Doctorado de Universidad de Ciencias de la Salud. Ramos Fernández,JM Facultativo Especialista de Área de Neuropediatría, Pediatría Hospital Materno-Infantil Regional Universitario de Málaga, Grupo de Investigación IBIMA. Ramos Fernández,JM, Moreno Pérez,D Departamento de Pediatría y Farmacología, Facultad de Medicina, Universidad de Málaga. Pérez Frías,J Facultativo Especialista de Área de Neumología pediátrica, Pediatría Hospital Materno-Infantil Regional Universitario de Málaga, Grupo de Investigación IBIMA. Pérez Frías,J Profesor Catedrático del Departamento de Pediatría y Farmacología, Facultad de Medicina, Universidad de Málaga. Moreno Pérez,D Infectología Pediátrica e Inmunodeficiencias, UGC Pediatría, Hospital Materno-Infantil, Hospital Regional Universitario de Málaga, Málaga, Spain. Moreno Pérez,D Grupo de Investigación IBIMA. Moreno Pérez,D Red de Investigación Translacional en Infectología Pediátrica (RITIP).

مصطلحات موضوعية: Pneumococcal conjugates vaccines, Pneumonia in children, Pediatrics, Hospitalization, Community-acquired infections, Pneumococcal vaccines, Pediatría, Neumonía, Hospitalizacion, Infecciones comunitarias adquiridas, Vacunas neumococicas, Niño, Adolescent, Preescolar, Estudios retrospectivos, Medical Subject Headings::Persons::Persons::Age Groups::Adolescent, Medical Subject Headings::Persons::Persons::Age Groups::Child, Medical Subject Headings::Persons::Persons::Age Groups::Child::Child, Preschool, Medical Subject Headings::Diseases::Bacterial Infections and Mycoses::Infection::Community-Acquired Infections, Medical Subject Headings::Check Tags::Female, Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunization, Medical Subject Headings::Persons::Persons::Age Groups::Infant, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Patient Care::Hospitalization::Length of Stay, Medical Subject Headings::Check Tags::Male, Medical Subject Headings::Diseases::Respiratory Tract Diseases::Pleural Diseases::Pleural Effusion, Medical Subject Headings::Chemicals and Drugs::Complex Mixtures::Biological Products::Vaccines::Bacterial Vaccines::Streptococcal Vaccines::Pneumococcal Vaccines

الوصف: International Journal of Infectious Diseases, official publication of the International Society for Infectious Diseases ; Introduction Community-Acquired Pneumonia (CAP) is one of the most frequent causes of hospital admission in children. Our objective is to measure the impact of the introduction of pneumococcal conjugate vaccines on the hospitalization of previously healthy children due to CAP. Method From 2011 to 2016, a partially retrospective, prospective, and descriptive study was carried out on healthy pediatric patients (3 months–14 years old) with CAP, who required hospital admission. Clinical, epidemiological, and demographic characteristics were collected, and vaccination status was obtained from medical records. Results A total of 292 cases were included, with a mean age of 33.4 months, 54% males. There was a progressive and significant 42% decrease in the number of admissions each year, without significant changes in the annual percentage of parapneumonic pleural effusion (PPE). Fifty-six percent of patients were immunized with a pneumococcal conjugate vaccine (PCV). The percentage of children who were not vaccinated decreased by 14%, and the coverage with PCV-13 increased by 46%. This revealed a significant increase of PPE in vaccinated patients with PCV-7 (63%) compared with unvaccinated (45%) and with PCV-13 (57%), without association with the presence of severe PPE. Moreover, no significant differences in severity or hospital stay were observed in unvaccinated patients, compared to those who were vaccinated. In >2-year-olds, we observed a significant increase in PPE (59%) compared to 45% in younger children. Conclusions The increase in vaccination coverage with PCV-13 resulted in a decrease in hospitalizations due to CAP and PPE. Vaccination with PCV-7 is associated in our sample with an increase in PPE but not with severe PPE nor an increase in the hospital stay. There was an epidemiological shift of severe forms of pneumonia and empyema at later ages (>2 years). ; Yes

وصف الملف: application/pdf

العلاقة: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S1201971220304690Test; Valdivielso Martínez AI, Ramos Fernández JM, Pérez Frías J, Moreno Pérez D. Influence of pneumococcal vaccination on the hospitalization of healthy pediatric patients due to typical Community-Acquired Pneumonia. Int J Infect Dis. 2020 Sep;98:194-199.; http://hdl.handle.net/10668/3469Test

الإتاحة: https://doi.org/10.1016/j.ijid.2020.06.034Test
http://hdl.handle.net/10668/3469Test

المؤلفون: Rodriguez Azor, Begona, Ramos Fernandez, Jose Miguel, Sanchiz Cardenas, Sonia, Cordon Martinez, Ana, Carazo Gallego, Begona, Moreno-Perez, David, Urda Cardona, Antonio

المساهمون: Rodriguez Azor, Begona Hosp Reg Univ Malaga, Hosp Materno Infantil, Unidad Gest Clin Pediat, Malaga, Spain, Sanchiz Cardenas, Sonia Hosp Reg Univ Malaga, Hosp Materno Infantil, Unidad Gest Clin Pediat, Malaga, Spain, Urda Cardona, Antonio Hosp Reg Univ Malaga, Hosp Materno Infantil, Unidad Gest Clin Pediat, Malaga, Spain, Ramos Fernandez, Jose Miguel Hosp Reg Univ Malaga, Hosp Materno Infantil, Unidad Gest Clin Pediat, Secc Lactantes, Malaga, Spain, Cordon Martinez, Ana Hosp Reg Univ Malaga, Hosp Materno Infantil, Unidad Gest Clin Pediat, Secc Lactantes, Malaga, Spain, Ramos Fernandez, Jose Miguel Grp Invest IBIMA, Malaga, Spain, Moreno-Perez, David Grp Invest IBIMA, Malaga, Spain, Moreno-Perez, David Univ Malaga, Fac Med, Dept Pediat & Farmacol, Malaga, Spain, Carazo Gallego, Begona Hosp Reg Univ Materno Infantil, Unidad Gest Clin Pediat, Secc Infectol, Malaga, Spain, Moreno-Perez, David Hosp Reg Univ Materno Infantil, Unidad Gest Clin Pediat, Secc Infectol, Malaga, Spain

مصطلحات موضوعية: Renal scar, Pyelonephritis Voiding cystourethrography, DMSA-scintigraphy, Urinary-tract-infection, Children, Diagnosis, Infants, Multicenter, Management, Resistance, Pathogens, Reflux

الوصف: Introduction: Acute pyelonephritis (APN) is one of the most common causes of serious bacterial infection in infants. Renal scarring is the most prevalent long-term complication.Objectives: To review the incidence of renal scarring within 6 months after an episode of APN in children under 36 months and its relationship with imaging studies, clinical settings, and bacteriology.Method: A retrospective study of previously healthy patients aged one to 36 months, admitted for a first episode of APN, with a minimum follow-up of 6 months. Demographic and clinical variables were collected along with bacteriology, renal and bladder ultrasound scan, voiding cystourethrography, DMSA-scintigraphy, and re-infection events.Results: A total of 125 patients were included in the study, of which 60% were male, the large majority (92%) febrile, and due to E. coli (74.6%). There was a history of prenatal ultrasound scan changes in 15.4%. Ultrasound scan found dilation of the urinary tract in 22.1%. Voiding cystourethrography was performed on 70 patients: 54.3% no abnormalities, 12.8% vesicoureteral reflux (VUR) grade I-III and 32.9% IV-V grade VUR. Six patients had IV-V grade VUR with a normal ultrasound scan. Adherence to DMSA-scintigraphy at 6 months was only 61% of that indicated. Renal scarring was found in 44.3% of those in which it was performed (60 cases).Conclusions: Almost half (44%) DMSA-scintigraphy in children aged one to 36 months hospitalised for APN show renal scarring at 6 months, which was found to be associated with the re-infection events and the IV-V grade VUR. There was no relationship between scarring and the bacteriology or the elevations of inflammatory biochemical markers. (C) 2015 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L.U. All rights reserved.

العلاقة: http://hdl.handle.net/10668/18683Test; https://doi.org/10.1016/j.anpedi.2016.03.002Test; 396182400004

الإتاحة: https://doi.org/10.1016/j.anpedi.2016.03.002Test
http://hdl.handle.net/10668/18683Test

المؤلفون: Guerrero‐del‐Cueto, Fuensanta, Ramos‐Fernandez, Jose Miguel, Leiva‐Gea, Isabel, Reina‐Moreno, Elena, Ortiz‐Ortigosa, Ana, Carazo‐Gallego, Begoña, Cordon‐Martinez, Ana Maria, Moreno‐Perez, David, Nuñez‐Cuadros, Esmeralda

المصدر: Pediatric Pulmonology ; volume 58, issue 4, page 1201-1209 ; ISSN 8755-6863 1099-0496

الوصف: Introduction Acute bronchiolitis is the main cause of hospitalization in children under 2 years of age, with a regular seasonality, mostly due to the respiratory syncytial virus. Objectives To describe the epidemiology of bronchiolitis hospitalizations in our center in the last 12 years, and analyze the changes in clinical characteristics, microbiology, and adverse outcomes during the SARS‐CoV‐2 pandemic. Methods Observational study including patients admitted for bronchiolitis between April 2010 and December 2021 in a Spanish tertiary paediatric hospital. Relevant demographic, clinical, microbiological, and adverse outcome variables were collected in an anonymized database. The pandemic period (April 2020 to December 2021) was compared to 2010−2015 seasons using appropriate statistical tests. Results There were 2138 bronchiolitis admissions, with a mean of 195.6 per year between 2010 and 2019 and a 2−4‐month peak between November and March. In the expected season of 2020, there was a 94.4% reduction of bronchiolitis hospitalizations, with only 11 cases admitted in the first year of the pandemic. Bronchiolitis cases increased from the summer of 2021 during a 6‐month long peak, reaching a total of 171 cases. Length of stay was significantly shorter during the pandemic, but no differences were found in clinical and microbiological characteristics or other adverse outcomes. Conclusions The SARS‐CoV‐2 pandemic has modified the seasonality of bronchiolitis hospitalizations, with a dramatic decrease in cases during the expected season of 2020−2021, and an extemporaneous summer−autumn peak in 2021 with longer duration but similar patient characteristics and risk factors.

الإتاحة: https://doi.org/10.1002/ppul.26322Test